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Purpose: Psoriasis vulgaris (PV) is an autoimmune-related chronic inflammatory disease of 
the skin, with both vascular and metabolic effects. Aggravating factors have been identified 
that initiate and maintain inflammation, including expression of Th1-, Th17-, and Th22-cell 
derived cytokines. Recently, we showed that the evolutionarily ancient and highly conserved 
damage-associated molecular pattern molecule “high mobility group box 1 (HMGB1)” is 
significantly increased in the serum of PV patients with disease progression and is decreased 
under standard therapies.
Materials and methods: To better understand the role of HMGB1 in the pathogenesis of PV, 
we recruited 22 untreated psoriatic patients with either mild or severe disease, defined by the 
Psoriasis Area Severity Index. We assessed HMGB1 and receptor for advanced glycation end 
products (RAGE) expression in the skin by immunohistochemistry and analyzed the immune-
phenotype of Treg and Th17 cells by flow cytometry.
Results: We found increased staining for HMGB1 in the dermis of psoriatic plaques in com-
parison to uninvolved skin of patients with PV. In addition, the major histocompatibility complex 
class III-encoded DNA and HMGB1 RAGE, induced by HMGB1, were highly expressed on 
psoriatic CD8+ T cells and CD4+ Treg. High expression of HMGB1 in the lesional skin was 
associated with even higher expression of its receptor, RAGE, on the cell surface of keratino-
cytes in patients with severe PV.
Conclusion: The presence of HMGB1 and RAGE signaling may impact orchestration of chronic 
inflammation in PV which might have implications for Treg and Th17 cells.
Keywords: HMGB1, RAGE, psoriasis vulgaris, Th17
Introduction
Psoriasis vulgaris (PV) is a chronic, immune-mediated disease that affects the skin 
and joints with a complex multigenic genetic architecture defined by genome-wide 
association studies.1 PV is one of the most common skin diseases with a prevalence 
of ~2% within the general population. It is associated with numerous comorbidities 
including increased cardiovascular risk or psoriatic arthritis in up to 25% of patients.2 
These comorbidities influence patients’ health and quality of life (CLCI), and con-
tribute to a 3- to 7-year reduction in life expectancy when severe.3 Thus, psoriasis is 
a systemic, inflammatory disease in which increased release of pro-inflammatory 
cytokines from immune-related cells associated with chronic activation of the innate 
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and adaptive immune systems are mechanisms that mediate 
long-term damage to multiple tissues and organ.1 Several key 
mechanisms have been proposed to participate in initiating 
and maintaining psoriasis, including activation of dendritic 
cells by self-DNA along with LL37, putative auto-antigens, 
or the release of pro-inflammatory mediators such as IL-17A, 
IL-23, or tumor necrosis factor.4 Neither the role of the DNA 
binding protein RAGE nor the chromatin-associated protein 
HMGB1 have been extensively studied in this disease.
The activation of keratinocytes leads to an increased 
production of antimicrobial peptides including the beta 
defensins, LL-37, and several skin homing chemokines, as 
well as DNA, perpetuating the inflammatory loop within the 
skin. However, the precise mechanism underlying the acti-
vation of keratinocytes in psoriasis is not fully clarified yet. 
The T-helper type-17 subset (Th17) produces, in addition to 
IL-17A, other inflammatory cytokines including IL-23, IL-6, 
IL-21, IL-1, or TGF-β that can interact with resident dermal 
cells including keratinocytes, dendritic cells, and endothelial 
cells.5 Monoclonal antibodies or soluble receptors for IL-17 
or IL-23 are promising modalities for targeted psoriasis 
therapy, as Th17 cells themselves are likely responsible for 
the chronic course of psoriasis.6
Th17 cells have key functions in several mouse autoim-
mune disease models and are thought to be similarly involved 
in human diseases.7,8 The mechanisms leading to the differ-
entiation of Th17 cells is still poorly understood in humans. 
Differentiated CD4+ T-cell subpopulations display a high 
grade of plasticity. Their initial differentiation along an indi-
vidual pathway is not necessarily a terminal end point in T-cell 
development. In particular, FOXP3+ regulatory T cells (Treg) 
and Th17 cells demonstrate a high grade of plasticity. This 
allows for a functional adaptation to various physiological 
situations during an ongoing immune response.9 In psoriasis 
vulgaris, Bovenschen et al showed that Treg can differentiate 
into Th17 cells, particularly when stimulated by IL-23.10 In 
other autoimmune diseases, including rheumatoid arthritis 
or graft-versus-host disease, HMGB1 modulates the Treg/ 
Th17 ratio toward IL-17-producing cells.11,12
The high mobility group nuclear proteins were discovered 
in 1973 in an effort to understand chromatin organization and 
later as specific regulators of gene expression.13 HMGB1, 
the predominant and most abundant member of this family, 
is a non-histone, chromatin-associated protein present in all 
metazoans within most eukaryotic cells, helping to stabilize 
and compact nucleosomes and acting to promote several 
transcriptional complexes including nuclear hormones, 
p53/p73 nuclear complexes, and others.14 HMGB1 within 
the cytosol promotes mitochondrial quality control and 
autophagy, but extracellular HMGB1 serves as the prototypic 
damage-associated molecular pattern (DAMP), functioning 
as a cytokine-like molecule, interacting promiscuously with 
several cytosolic and cell surface receptors.15 It is released 
passively during heightened autophagy or cellular necrosis 
as well as being secreted actively by immune cells including 
monocytes, macrophages, and dendritic cells.16 We recently 
demonstrated that serum levels of HMGB1 correlate with 
disease progression of PV and are decreased following treat-
ment with standard therapies.17 HMGB1 has been shown to 
interact with toll-like receptors 2 (TLR2) and 4 (TLR4) on 
keratinocytes in an imiquimod-induced psoriasis like mouse 
model.18 Following blockade of HMGB1, reduced numbers 
of infiltrating CD3+ T cells and CD4+ RORγt+Th17 cells 
in psoriasiform lesions, as well as reduced serum levels of 
IL-17, could be demonstrated.19
Here, we focused on expression of HMGB1 within the skin, 
and analyzed in those same patients, peripheral blood immune 
cells, especially Treg and Th17 cells, as potential sequelae of 
heightened HMGB1 release and signaling in patients.
Materials and methods
study participants
The study group used for flow cytometric analysis consisted 
of 22 patients with PV, who were recruited at the Department 
of Dermatology, University of Essen, Germany, between 
2013 and 2014. Ten healthy subjects were recruited from 
current or retired members of the clinic staff. All controls 
and patients were medically healthy, except for the patients 
who suffered from PV. All participants provided written 
informed consent according to the Declaration of Helsinki 
and obtained approval of medical ethics committee of the 
University Hospital Essen.
Psoriasis disease severity of the patients was measured by 
the Psoriasis Area Severity Index (PASI). The PASI includes 
the percentage area affected by psoriasis, which is evaluated in 
the following four regions of the body (head and neck, upper 
limbs, trunk, and lower limbs), and the intensity of redness, 
thickness, and scaling of the plaques. Medium to severe dis-
ease was defined by a PASI score <15 and mild disease by a 
PASI score <5. Eleven patients with mild PV, eleven patients 
with severe PV, and ten healthy controls were included in this 
study (Table 1). The mean age was 46, 41, and 31 years for 
the two patient groups and individual controls, respectively.
Skin samples were obtained from five patients with severe 
PV, five patients with mild PV, and four healthy controls 
(Table 2). Two skin samples were taken from each of these 
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PV patients: one of a psoriatic plaque (lesional) and one of 
unaffected/ healthy skin (uninvolved). All biopsies were taken 
from the upper limb. The mean age was 48, 42, and 23 years 
for the patients and controls, respectively.
The patients had no local or systemic therapy for at least 
4 weeks. A systemic treatment for PV had been terminated 
for at least 3 months before study inclusion.
immunohistochemistry
Tissue sections of 5 µm were generated after embedding the 
skin biopsies in paraffin. To analyze the presence of human 
T cells and IL-17 expressing cells in the skin samples, a 
double immunostaining was conducted according to the 
manufacturer’s protocol using antihuman primary antibodies 
directed against CD3 (general T-cell marker, F7.2.38; Abcam, 
Cambridge, UK) and IL-17A (polyclonal goat; R&D Sys-
tems, Minneapolis, MN, USA), respectively. In this double 
immunostaining, first the presence of IL-17 expressing cells 
was established; to this end, antigens were retrieved by boil-
ing the sections in Tris/EDTA buffer (50 mM Tris, 2 mM 
EDTA, pH 9.0). The sections were washed, preincubated for 
15 minutes with 20% normal swine serum, and incubated 
overnight with anti-IL-17A antibody (1:500). To detect 
IL-17A-producing cells, the sections were stained using 
the labeled streptavidin-biotin (LSAB) method (Universal 
LSAB Kit/AP; Dako, Jena, Germany) and visualized using 
permanent red chromogen (Dako). Finally, for the second 
immunostaining procedure, the sections were preincubated 
as described earlier and incubated overnight with anti-CD3 
antibody (1:50). CD3 expressing cells were detected by the 
LSAB method and visualized using vector blue (Vector 
Laboratories, Philadelphia, PA, USA).
To detect the expression of HMGB1 in the skin samples, 
single immunostaining was conducted using anti-HMGB1 
antibody according to the manufacturer’s protocol (Novus 
Biologicals, Littleton, CO, USA). After deparaffinization 
and rehydration, heat-induced antigen retrieval with citrate 
buffer (pH 6) was performed for 30 minutes. After washing 
and applying the endogenous peroxidase block for 15 min-
utes, sections were incubated with 1% bovine serum albumin 
(BSA; Dako). The antibody was applied (anti-HMGB1-Ab, 
1:200) dissolved in 1% BSA, and sections were incubated 
overnight. The sections were sequentially washed and incu-
bated with Envision+ System HRP labeled polymer anti-
rabbit (Dako; for HMGB1) and visualized with DAB cobalt. 
HMGB1 was counterstained with Mayer’s hematoxylin 
(Sigma-Aldrich Co., St Louis, MO, USA).
All sections were washed in tap water, dehydrated, 
and mounted using Permount (Thermo Fisher Scientific, 
Waltham, MA, USA). Sections were photographed at an 
objective magnification of 20× or 40× using a microscope 
(Axioskop2 MOT; Zeiss, Sliedrecht, the Netherlands), digital 
camera (Axiocam MRc5; Zeiss), and AxioVision software 
(Zeiss).
For quantification of positive cells, images were saved 
at 10× objective magnification. The total epidermal area 
and positive respective markers area were measured. To 
quantify the cell counts in the dermis, a representative the 
region of interest (ROI) was drawn from the lowest epidermal 
papilla till 300 µm depth in the dermis using ImageJ and 
counted as the number of cells per mm.2 Cell numbers were 
independently analyzed by two researchers. The presence 
of HMGB1, IL-17, and CD3 was measured in the dermis of 
the skin samples.
Flow cytometry and antibodies
Peripheral blood cells were phenotypically analyzed by 
four- and ten-color immunofluorescence. Briefly, peripheral 
blood mononuclear cells were washed twice with buffer (PBS 
containing 0.2% BSA) and labeled with the antibodies of 
interest conjugated with FITC, PE, ECD, PE-CY5/APC, or 
PE-CY7. Cells were incubated for 20 minutes in the dark at 
room temperature, washed twice, and analyzed on a Coulter 
Epics XL flow cytometer (Beckman Coulter, Fullerton, CA, 
USA). A total of 5,000–10,000 living cells were collected 
and analyzed. Isotype-matched antibodies were used to define 
marker settings. The following conjugated antibodies were 
used: CD4 (UCHT1; Beckman Coulter), CD4 (MT310; 
Table 2 Demographics of the study subjects for tissue samples
Group No. of 
patients
Age (years) 
median range
F M
healthy controls 4 23 (22–23) 1 3
Patients with Pasi <5 5 42 (26–53) 4 1
Patients with Pasi >20 5 48 (28–73) 1 4
Abbreviation: Pasi, Psoriasis area severity index.
Table 1 Demographics of the study subjects for evaluation of 
peripheral blood
Group No. of 
patients
Age (years) 
median
F M
healthy controls 10 31 (21–55) 4 6
Patients with  Pasi <5 11 41 (21–48) 4 7
Patients with Pasi >20 11 46 (18–75) 3 8
Abbreviation: Pasi, Psoriasis area severity index.
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Dako), CD4 (38261; BioLegend, San Diego, CA, USA), CD8 
(SFCI21Thy2D3; Beckman Coulter), CD25 (M-A251; BD, 
Franklin Lakes, NJ, USA), CD127 (R34.34; Beckman Coul-
ter), TLR4 (HTA125; eBioscience, San Diego, CA, USA), 
TLR2 (TL2.1; eBioscience), RAGE (polyclonal; Biologo, 
Kronshagen, Germany), IL23R (218213; RD Systems), and 
CCR6 (11A9; BD).
To detect the intra-cytoplasmic cytokines or the tran-
scription factors FOXP3 (PCH101; eBioscience) and RORγt 
(AFKJS-9; eBioscience), the cells of interest were fixed 
and permeabilized (Fix and Perm reagent A and B; Caltag 
Laboratories, Vienna, Austria) according to the instructions 
of the manufacturer and, thereafter, labeled with the mono-
clonal antibody of interest. After 45-minute incubation at 
room temperature, the cells were washed three times and 
analyzed by flow cytometry. Appropriate isotype control 
monoclonal antibodies were used for marker settings. Data 
were analyzed by Kaluza Flow Cytometry Analysis Software 
(Beckman Coulter).
statistical analyses
The data of flow cytometry and immune histochemistry of 
the three different groups (patients with mild and severe PV 
and healthy controls) were compared using the nonparametric 
Mann–Whitney U test. Statistical analyses were performed 
using the GraphPad Prism 5 software. A value of P<0.05 was 
considered statistically significant.
Results
increased hMgB1 expression in the 
dermis of patients with psoriasis vulgaris
We analyzed the expression of HMGB1 in lesional and 
non-lesional skin biopsies of recently recruited psoriatic 
patients and healthy controls, using immunohistochemistry. 
The histopathological features of the two biopsy locations of 
a psoriatic patient are illustrated in Figure 1C and D. With 
respect to the general histology, lesional skin (Figure 1C) 
revealed the characteristic psoriatic features of thickened 
epidermis, parakeratosis, elongated rete ridges, and a mixed 
cellular infiltrate. A detailed view of lesional skin (Figure 
1D) shows the accumulation of HMGB1 expressing cells in 
the dermis along with cytosolic and extracellular HMGB1. 
The distant uninvolved skin (Figure 1B) did not reveal 
any pathological changes and lacks HMGB1 extranuclear 
expressing cells.
In the lesional dermal skin of mild and severe psoriatic 
patients, we found a significant higher number of HMGB1 
extranuclear positive cells as compared with healthy con-
trols (mean ± SD; 1,164±672.9 HMGB1 expressing cells/
mm2, n=5; 2,142±809.4, n=5; 257±154.2, n=4; P=0.0159; 
Figure 1 hMgB1 staining is enhanced in the dermis of psoriatic skin compared with uninvolved skin.
Notes: (A) hMgB1 in the dermis of healthy controls (n=4) and patients with mild (n=5) and severe (n=5) psoriasis vulgaris was assessed using immunostaining. cutaneous 
cytokine levels in individual patients as well as mean levels are shown. *P<0.05, Mann–Whitney U test. (B) immunostaining of hMgB1 of uninvolved skin in a psoriatic patient. 
(C) immunostaining of hMgB1 of a skin biopsy out of a psoriatic plaque (lesional skin). (D) Detailed view of hMgB1 molecules in dermal immunostaining. red circles indicate 
hMgB1-positive cells.
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respectively; Figure 1A). The percentage of extranuclear 
HMGB1 expressing cells in the lesional dermis related with 
disease progression (Figure 1A).
Within psoriatic patients, the uninvolved dermis revealed 
fewer numbers of extranuclear HMGB1 expressing cells/
mm2 dermis than the lesional skin samples. In the unin-
volved dermis of the mild psoriatic patients, the number of 
extranuclear HMGB1 expressing cells was similar to that 
found in the dermis of the healthy controls (mean ± SD; 
256±173.5 HMGB1 expressing cells/mm2, n=5; 257±154.2, 
n=4; Figure 1A). Interestingly, in the uninvolved dermis of 
the severe psoriatic patients, we measured approximately 
double the amount of extranuclear HMGB1 expressing cells 
as compared to patients with mild psoriasis and healthy 
individuals (mean ± SD; 499±203.4 extranuclear HMGB1 
expressing cells/mm2, n=5; 256±173.5, n=5; 257±154.2, n=4; 
respectively) (Figure 1A).
Lesional skin, thus, reveals the highest levels of extranu-
clear HMGB1 expressing cells, suggesting a correlation with 
disease activity; HMGB1 expressing cells in non-lesional 
skin were only increased in severe PV patients.
il-17a and cD3 expression in the 
dermis
Th17 cells and their signature cytokine IL-17A are known 
to play a key role in the pathogenesis of psoriasis vulgaris.20 
Also, in psoriatic patients, phenotypic Tregs are found to 
secrete IL-17.10 HMGB1 seems to influence the balance of 
Th17 cells and Tregs toward IL-17-producing cells.11,12,21,22 
To characterize the IL-17-producing T cells, we analyzed 
the presence of CD3 and/or IL-17-producing cells in skin 
biopsies of psoriasis patients and healthy controls by immu-
nostaining for both CD3 and IL-17A (Figure 2A–E).
As expected in lesional dermis of both patients with 
severe or mild PV, the number of CD3 expressing cells was 
higher as compared to that in the dermis of healthy controls 
(mean ± SD; 314±215 CD3+ cells/mm2, n=5; 303±279.4, 
n=5; 15±9, n=4; P=0.0179, Figure 2G). This implies on aver-
age a 20-fold, significant increase in T cells in the lesional 
dermis of psoriatic patients as compared to the dermis of 
healthy controls, and this was observed irrespective of disease 
severity, confirming the results of others.23
The uninvolved skin of mild psoriatic patients showed 
similar CD3 expression levels, as found in the dermis of 
healthy controls, whereas the severe psoriatic group showed 
a higher number of CD3 expressing cells (55±37, n=5; 
15.8±6.1, n=5; and 15.3±9, n=4 in severe PV vs mild PV, 
and healthy controls, respectively) (Figure 2G).
Lesional skin of both mild and severe PV patients 
revealed strongly increased levels of CD3+ T-cell expres-
sion, while an increase of CD3 in non-lesional skin was only 
observed in severe PV patients.
The presence of IL-17-producing T cells, as indicated by 
IL-17 and CD3 coexpression, shows a trend toward higher 
numbers in the transition from uninvolved to lesional skin. 
In the uninvolved dermis of PV patients and healthy controls, 
the numbers of CD3+ IL-17+ cells were very low (mean ± 
SD; 1.7±0.9 CD3+ IL-17+ cells / mm2, n=5; 4±2.9, n=5; 
0.5±1.1, n=4; respectively) (Figure 2H). Conversely, in the 
lesional dermis of mild and severe psoriatic patients, we 
detected the presence of CD3+ IL-17+ cells (mean ± SD; 
11±10.6, n=5; 12±7.5, n=5; 0.5±1.1, n=4; P=0.0179). We 
observed a significantly higher number of IL-17+ T cells in 
the lesional dermis of psoriatic patients compared to healthy 
controls (Figure 2H). Most of the IL-17A found in the skin of 
psoriatic patients and healthy controls was not associated with 
CD3 (Figure 2F), and could well be expressed by neutrophils 
or mast cells, as has been previously reported for psoriatic 
skin.24–26 In the lesional dermis of psoriatic patients, a trend 
to higher numbers of single IL-17A expressing cells was 
found as compared to the dermis of healthy donors (mean 
± SD; 52±19.3, n=5; 59±37.3, n=5; 20±15.2, n=4; P=0.11 
and P=0.064, in severe, mild patients, and healthy controls, 
respectively) (Figure 2F). In the uninvolved dermis of the 
severe psoriatic patients, as compared to the dermis of mild 
psoriatic patients or healthy controls, we observed a trend 
toward higher expression of single IL-17A expressing cells 
(40±18.2, n=5; 25±15, n=5; 20±15.3, n=4 in severe PV vs 
mild PV, and healthy controls, respectively) (Figure 2F).
immune cell surface expression of rage, 
Tlr2, and Tlr4
After having observed increased numbers of IL-17-producing 
CD3+ cells and elevated levels of HMGB1 molecules in 
the psoriatic skin, we examined peripheral blood mono-
nuclear cells for the expression of receptors for HMGB1. 
TLR2, TLR4, and RAGE are defined signaling receptors 
for HMGB1. Hence, we measured the expression of these 
receptors on the surface of CD4+ and CD8+ cells, as well 
as on CD4+ Treg, defined by CD4+ CD25highCD127low 
surface expression as previously described by Liu et al, in 
the peripheral blood of patients with psoriasis vulgaris and 
healthy controls using flow cytometry.27
There was no difference in the expression level of the 
receptors TLR2 and TLR4 and RAGE between healthy 
donors, mild or severe psoriatic patients (data not shown and 
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Figure 3A). Subgroup analysis revealed that the percentage 
of RAGE expressing CD4+ cells in the peripheral blood of 
psoriatic patients, however, decreased with disease progres-
sion (8.9%, 11.2%, and 13.1% of all CD4+ cells were positive 
for RAGE in severe PV (n=11), mild PV (n=11), and healthy 
controls (n=10), respectively) (Figure 3B).
Increased percentages of RAGE expressing CD8+ 
cells were found in PV patients as compared to the healthy 
controls (6.8%, 5.8%, and 3.4% in severe PV, mild PV, and 
healthy controls, respectively; P=0.0276) (Figure 3C) with 
expression positively correlating with disease progression. 
The percentage of CD4+ Treg that expressed RAGE on 
their surface was also significantly higher in the peripheral 
blood of psoriatic patients as compared with healthy controls 
(9.3%, 4.25%, and 3.9% of the gated CD4+ Treg were posi-
tive for RAGE in severe PV, mild PV, and healthy controls, 
respectively; P=0.0195) (Figure 3D–F). Of note, increased 
numbers of RAGE expressing CD8+ cells and CD4+ Treg 
Figure 2 Marked increases in il-17 expression and cD3+ T cells within the dermis of affected skin.
Notes: (A) immunostaining of il-17 (red) and cD3 (blue) of an uninvolved skin biopsy of a psoriatic patient. (B) immunostaining of il-17 (red) and cD3 (blue) of a skin 
biopsy out of a psoriatic plaque (lesional skin). (C) Detailed view of il-17 staining in immunohistochemical analysis. (D) Detailed view of a cD3+ cell in the immunostaining. 
(E) Detailed view of a il-17+ cD3+ cell in the double immunostaining. (F–H) il-17, cD3, and il-17+ cD3 double staining in the dermis of healthy controls (n=4) (F) and 
patients with mild (n=5) (G) and severe (n=5) (H) psoriasis vulgaris assessed with immunostaining. cutaneous il-17 expressing cells/mm2 in individual patients as well as the 
arithmetic mean are shown. *P<0.05, Mann–Whitney U test.
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Figure 3 expression of rage on the surface of cD8+ and cD4+ T cells as well as cD4+ regulatory T cells correlates with disease severity.
Notes: Flow cytometry of rage expression on all live immune cells (A), cD8+ T cells (B), cD4+ T cells (C), and cD4+ Treg (D) of healthy controls (n=10) and patients 
with mild (n=11) and severe (n=11) psoriasis vulgaris. Representative flow plots are displayed for RAGE+ Tregs in patients (E) and controls (F). rage expressions in 
individual patients as well as arithmetic means are shown. *P<0.05, **P<0.01, Mann–Whitney U test.
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are paralleled by increased serum levels of HMGB1, as we 
previously reported, in severe psoriatic patients, suggesting 
a possible HMGB1–RAGE relationship that is consistent 
with HMGB1’s ability to upregulate and induce RAGE 
expression.17
rOrγt, ccr6, and il-23r expression on 
cD4+ cells and cD4+ Treg in patients 
with PV
HMGB1 decreases the Treg/Th17 ratio in individual auto-
immune diseases.11,21,22,28,29 Thus, we examined whether 
increased HMGB1 and RAGE expression in PV was associ-
ated with increased Th17 levels in the peripheral blood of 
PV patients and healthy controls using flow cytometry. We 
examined both CCR6 and IL-23-receptor (IL-23R) surface 
expression, and the intracellular expression of the transcrip-
tion factor RORγt as markers for Th17 cells.30
CD4+ lymphocytes expressing CCR6 and IL-23R on 
their surface were significantly increased in the peripheral 
blood of severe psoriatic patients (0.7%, 0.35%, and 0.4% in 
severe PV, mild PV, and healthy controls; P=0.0385) (Figure 
4A). Also, the number of CCR6 and IL-23R expressing 
CD4+ Treg was increased in severe psoriatic patients (1.2%, 
0.5%, and 0.6% in severe PV, mild PV, and healthy controls; 
P=0.0195) (Figure 4B).
In contrast, we observed a trend toward reduced percent-
ages of RORγt+cells in PV patients as compared to healthy 
controls in both the CD4+ CD25highFOXP3high Treg (2.2%, 
3.3%, and 4% in severe PV, mild PV, and healthy controls) 
(Figure 5A) and total CD4+ population (1.7%, 1.6%, and 
1.0% in severe PV, mild PV, and healthy controls) (Figure 
5B). The percentages of thymic-derived FOXP3+ CD4+ Treg 
in the peripheral blood of PV patients and healthy controls 
were similar (data not shown).
Figure 4 Markedly enhanced coexpression of ccr6 and the il-23 receptor on the surface of cD4+ Tregs and cD4+ T cells within affected skin.
Notes: Flow cytometric assessment of ccr6 and il-23 receptor on cD4+ T cells (A) and cD4+ Treg (B) of healthy controls (n=10) and patients with mild (n=11) or severe 
(n=11) psoriasis vulgaris. ccr6 and il-23r expressions in individual patients as well as the arithmetic mean are shown. *P<0.05, Mann–Whitney U test.
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Discussion
HMGB1 is emerging as a centrally important factor found in 
the serum of patients with trauma, sepsis, cancer, and vari-
ous inflammatory disorders.31–33 We previously demonstrated 
that HMGB1 levels were increased in the sera of psoriatic 
patients, and these levels related to disease progression. 
Moreover, upon standard psoriasis therapy, we found a reduc-
tion in these HMGB1 serum levels.17 These previous finding 
suggests a role for HMGB1 and by extension, its receptors 
TLR2, TLR4, and/or RAGE in the immune pathology of 
psoriasis.
In the present work, we show that HMGB1 express-
ing cells are significantly increased in the skin of psoriatic 
patients and that its receptor RAGE is highly expressed on the 
cell surface of both circulating CD8+ cells and CD4+ Treg 
in patients with psoriasis vulgaris, which is linked to disease 
progression. Furthermore, we measured a higher number of 
IL-17-producing cells in the lesional skin of psoriatic patients 
in comparison to the uninvolved skin of the same patient, or 
the skin of healthy controls. We also detected an increased 
expression of IL-23-receptor and CCR6 on CD4+ cells, as 
putative Th17 cells, and CD4+ Treg.
HMGB1 is a chromatin-associated molecule that acts to 
promote access to various transcription factors, stabilizing 
nucleosomes and further compacting the DNA.34 During 
stress, it is released by macrophages or by necrotic cells, 
acting as a pro-inflammatory molecule to promote a wound 
healing response, recruiting mesangioblasts, neutrophils, 
platelets, macrophages, and ultimately adaptive immune cells 
in several autoimmune diseases and cancer.35–37 HMGB1 is 
thus the prototypic DAMP molecule or an endogenous dan-
ger signal.16,38 Our findings deepen and extend this work to 
demonstrate its presence in the skin of patients with psoriasis 
as well as peripheral blood serum and cellular changes, cor-
relating with disease severity.
Several studies have highlighted involvement of HMGB1 
in individual autoimmune diseases. For example, in skin 
lesions of patients with lupus erythematosus, in the sera of 
patients with systemic sclerosis, or in the minor salivary 
glands of patients with Sjogren’s syndrome elevated concen-
trations of HMGB1 are found.39–41 The role of HMGB1 in 
these autoimmune diseases has not yet been fully elucidated. 
An emergent finding in the last 5 years has been that HMGB1 
signaling promotes conversion of Treg into IL-17-producing 
cells. This differentiation has been shown in graft-versus-
host disease, hepatitis B, rheumatic arthritis, autoimmune 
myocarditis, and atherosclerosis.11,12,21,22,29 This shift away 
from Tregs promotes tissue destruction and production of 
pro-inflammatory Th17 cells. Uncontrolled differentiation of 
Treg into Th17 cells could be an important step in the onset 
and maintenance of autoimmune diseases. In PV, Treg readily 
differentiate into IL-17-producing cells. This differentiation 
was promoted by the cytokine IL-23 and correlated with the 
loss of FOXP3 and enhancement of RORγt expression.10
We analyzed the expression level of these three receptors 
of HMGB1 on the surface of peripheral blood immune cells 
and found a significant average twofold increase of RAGE 
expression on the surface of Treg and CD8+ cells of severe 
psoriatic patients as compared to healthy donors. The expres-
sion levels of TLR2 and TLR4 showed no difference in our 
psoriasis and healthy control groups. HMGB1 in the serum 
likely promotes the expression of RAGE as the predominant 
altered receptor (when compared with TLR2 and TLR4) in 
the peripheral blood. HMGB1 and its receptor RAGE on Treg 
and on CD8+ cells play a role in the pathogenesis of psoria-
sis, suggesting that efforts to target these molecules could 
indeed be part of the armamentarium for treating patients.42,43 
We described earlier that the differentiation of Treg into IL-
17-producing cells is accompanied by a higher expression 
of the transcription factor RORγt, a marker for Th17 cells.44 
Higher expression levels of RORγt and a decrease of FOXP3 
following in vitro stimulation with HMGB1 of peripheral 
mononuclear cells of patients with hepatitis B and athero-
sclerosis was found.21,29 Our analysis revealed that peripheral 
blood T cells showed decreased RORγt expression in Treg 
and CD4+ cells with disease progression in patients with PV. 
IL-17-producing cells, which express higher percentages of 
RORγt, might be recruited to the location of primary inflam-
mation in the skin or are induced at site. Indeed, we observed 
that Th17 cells were overrepresented in lesional psoriatic 
skin, representing 49%–93% of CD4+ cells compared with 
3%–18% in peripheral blood of these patients and increased 
following in vitro– activation to a greater extent than cells in 
the periphery.45 Immunostaining of CD3 and IL-17 revealed 
higher numbers of CD3+ IL-17+ cells in the lesional skin 
when compared to uninvolved skin of a psoriatic patient or 
healthy controls, indicating the possible relevance of these 
cells at site and for disease progression.
We showed a significant increase of Treg and CD4+ 
cells expressing CCR6 and IL-23R in the peripheral blood 
of severe psoriatic patients. The combined expression of 
these two receptors is a useful marker to identify (precur-
sor) Th17 cells. Expression of CCR6 precisely identified 
all IL-17-producing T cells with differing levels of RORγt 
expression. Th17 clones derived from these cells not only 
expressed RORγt, but also remarkable amounts of the Th1 
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transcription factor T-bet.30 These results highlight that the 
initial apparent differentiation of T cells is contradicted by a 
high grade of plasticity of T cells, allowing functional adap-
tation to various physiological situations during an ongoing 
immune response.9
Following injection of HMGB1-neutralizing antibody 
in the peritoneal cavity of mice with psoriatic lesions, 
reduced numbers of infiltrating CD3+ T cells and CD4+ 
RORγt+Th17 cells in psoriatic lesions were found, as well 
as reduced serum levels of IL-17.19 HMGB1 itself promotes 
the Th17 immune response in PV via caspase 1 cleavage 
and subsequent release of IL-18 from keratinocytes.19 We 
found that HMGB1 could also interact directly with CD4+ 
Treg and CD8+ cells via binding to RAGE.17 Inhibition of 
HMGB1 suppresses immigration of immune cells in the skin 
and secretion of pro-inflammatory cytokines in the peripheral 
blood of psorasiform mice.19 Targeting HMGB1 seems a 
rational target for therapy of patients with psoriasis vulgaris.
Conclusion
The role of HMGB1 in autoimmune diseases and especially 
PV is likely due to secretion by keratinocytes and several 
types of immune cells including activated macrophages, 
mature dendritic cells, and natural killer cells in response 
to injury, infection, or other inflammatory stimuli.37,46,47 It 
plays an important role in the pathogenesis of PV by influ-
encing homeostasis, limiting the natural immunosuppressive 
phenotype and promoting pro-inflammatory conditions. We 
speculate that the interaction of HMGB1 promotes RAGE 
expression, thereby driving a Th17 shift in patients with PV 
and promoting persistence of the inflammatory state. More 
detailed functional assays will be needed to fully evaluate the 
association of serum and skin cytokine levels of HMGB1, 
the expression of RAGE on psoriatic Treg, and the shift from 
regulatory T cells to Th17-like cells. Our studies promote 
a subsequent study with larger patient cohort and further 
defined immune subsets to evaluate targeting HMGB1 as a 
biomarker or as a potential therapeutic target during disease 
progression of PV.
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